Abstracts Archive - Page 5 of 2607 - ACR Meeting Abstracts

Abstract Number: 0049 • ACR Convergence 2025
Enhanced Src Homology Region 2 Domain-containing Phosphatase 1 Activity Ameliorates Murine Inflammatory Arthritis Through the Innate Immune System
Jun Li, Katalin Mikecz and Adrienn Markovics, Rush University Medical Center, Chicago
Background/Purpose: Src homology region 2 domain-containing phosphatase 1 (SHP-1) is a cytoplasmic protein tyrosine phosphatase expressed in hematopoietic cells (PMID9069265). SHP-1 is a key negative…
Abstract Number: 0038 • ACR Convergence 2025
DNA Methylation Signatures of Smoking in Labial Salivary Gland Tissue in a Sjögren’s Disease Cohort
Priya Bhatt¹, Mary Horton², Caroline Shiboski³, Lisa Barcellos⁴ and Lindsey Criswell², ¹Mayo Clinic Alix School of Medicine, Toledo, ²NIH/NHGRI, Bethesda, MD, ³University of California San Francisco, San Francisco, CA, ⁴UC Berkeley, Berkeley
Background/Purpose: Cigarette smoking has been linked to the development of several autoimmune diseases, including Sjögren’s Disease (SjD). Since DNA methylation (DNAm) is altered by cigarette…
Abstract Number: 0056 • ACR Convergence 2025
Repository Corticotropin Injection Reduces Inflammation and Bone Turnover Markers in the Murine CIA Model
Maripat Corr¹, Grace Hsueh², Aaron place², David Lucas² and NANCY LANE³, ¹ucsd, San Diego, CA, ²ANI Pharmaceuticals, Inc., Baudette, MN, ³University of California at Davis, School of Medicine, Sacramento, CA
Background/Purpose: Melanocortin receptor agonists, such as adrenocorticotropic hormone (ACTH), are anti-inflammatory with pleotropic functions. We aimed to evaluate the effects of a repository corticotropin injection…
Abstract Number: 0032 • ACR Convergence 2025
Protein Language Model-Guided Homology Identifies Microbial Enzymes Linked to Fibrosis-Prone IgG4-RD and Crohn’s Disease
Kumar Thurimella¹, Ahmed Mohamed², Chenhao Li³, Tommi Vatanen⁴, Daniel Graham³, Roisin Owens⁵, Sabina Leanti La Rosa⁶, Damian Plichta³, Sergio Bacallado⁵ and Ramnik Xavier⁷, ¹University of Colorado School of Medicine, Aurora, CO, ²Broad Institute, Boston, ³Broad Institute, Cambridge, MA, ⁴University of Helsinki, Helsinki, Finland, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶NMBU, As, Norway, ⁷Harvard Medical School, Boston, MA
Background/Purpose: Uncharacterized microbial enzymes in metagenomics are difficult to annotate, especially in fibrosis-prone conditions like IgG4-related disease (IgG4-RD) and Crohn’s disease (CD), where microbial carbohydrate…
Abstract Number: 0022 • ACR Convergence 2025
Genome-wide association study identifies novel genetic risk factors for rheumatoid arthritis-associated interstitial lung disease
Austin Wheeler¹, Thomas Riley², Riku Takei³, Joshua Baker², Yangyuna Yang¹, Punyasha Roul⁴, Katherine Wysham⁵, Grant Cannon⁶, Gary Kunkel⁷, Gail Kerr⁸, Dana Ascherman⁹, Paul Monach¹⁰, Andreas Reimold¹¹, Jill Poole¹, Ted Mikuls¹, Tony Merriman¹² and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pennsylvania, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴UNMC, Omaha, NE, ⁵VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁶University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰VA Boston Healthcare System, Boston, MA, ¹¹Dallas VA Medical Center, Dallas, TX, ¹²University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Interstitial lung disease (ILD) is clinically present in ~10% of individuals with RA. There is recognized overlap between RA-ILD and idiopathic pulmonary fibrosis (IPF)…
Abstract Number: 0010 • ACR Convergence 2025
XmAb657, a CD19 x CD3 T-Cell Engaging Bispecific Antibody for Autoimmune Disease
Matthew Bernett¹, Gregory Moore², Katrina Bykova², Viralkumar Davra², Seung Chu², Michael Sheard², Ruschelle Love², Norman Barlow², Engie Salama², Jitendra Kanodia², Panida Lertkiatmongkol², Dipankar Chaudhuri², Kendra Avery², Hanh Nguyen², Rumana Rashid², Ke Liu², Jing Qi², Araz Eivazi², Thuy Truong², Sher Karki², James Ernst², Rena Bahjat² and John Desjarlais², ¹Xencor, Inc., Pasadena, CA, ²Xencor, Inc., Pasadena
Background/Purpose: B cell depletion is a validated therapeutic strategy in autoimmune disease, but current approaches targeting CD20 may only partially eliminate disease-driving subsets such as…
Abstract Number: 0037 • ACR Convergence 2025
A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
Natalie McCormick¹, Sharan Rai², Chio Yokose³, Tony Merriman⁴, Robert Terkeltaub⁵ and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Retired, San Diego, CA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular (CV) mortality which has failed to improve over recent decades,…
Abstract Number: 0007 • ACR Convergence 2025
WITHDRAWN
Abstract Number: 0028 • ACR Convergence 2025
Computational and Laboratory Identification of Risk-Driving Alleles on Juvenile Idiopathic Arthritis (JIA)-Associated Haplotypes
Adam He¹, Hannah Ainsworth², Kaiyu Jiang³, Ekaterina Khtovatkova², Yanmin Chen³, Carl Langefeld⁴, Charles G Danko¹ and James N. Jarvis⁵, ¹Cornell University Baker School of Veterinary Medicine, Ithaca, NY, ²Wake Forest University, Winston-Salem, NC, ³University of Washington School of Medicine, Seattle, WA, ⁴Wake Forest University School of Medicine, Winston Salem, NC, ⁵University of Washington Center for Indigenous Health, Seattle, WA
Background/Purpose: Multiple genomic regions are known to confer risk for JIA. However, identifying the SNPs that exert the biological effects that confer risk, and therefore…
Abstract Number: 0025 • ACR Convergence 2025
Expansion and Transcriptional Reprogramming of CD14⁺ and CD16⁺ Monocytes in Behçet’s Disease
Elio Carmona¹, Rabia Deniz², Cemal Bes³, Haner Direskeneli⁴, Ahmet Gul⁵ and Amr Sawalha⁶, ¹Division of Pediatric Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Pittsburgh, ²University of Health Sciences Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ³University of Health Sciences, Basaksehir Çam and Sakura City Hospital, Istanbul, Turkey, ⁴Marmara University, ISTANBUL, Turkey, ⁵Istanbul University, Istanbul, Turkey, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Behçet’s disease (BD) is a chronic, relapsing inflammatory disease characterized by complex immunopathogenesis and limited treatment options. Monocytes are known to play a significant…
Abstract Number: 0021 • ACR Convergence 2025
DoCTIS: A Single Cell RNA-Seq Atlas of Drug Response To Targeted Therapies
Antonio Julià¹, Yolanda Guillén², Paloma Vela Casasempere³, Antonio Fernández Nebro⁴, Carlos Marras⁵, Santos Castañeda⁶, Jaime Calvo Alén⁷, Jesús Tornero Molina⁸, Juan Cañete⁹, Eugeni Domènech¹⁰, Javier Gisbert¹¹, Jose M. Carrascosa¹², Eduardo Fonseca¹³, Luis Bujanda Fernández De pierola¹⁴, Valle García Sánchez¹⁵, Britta Siegmund¹⁶, Giampiero Girolomoni¹⁷, Holger Heyn¹⁸, Laura Jiménez Gracia¹⁸, Pere Santamaria¹⁹, Edgar Angelats²⁰, Richard Myers²¹, Sergio H. Martínez Mateu², Juan Ángel Patiño Galindo², Ernest Choy²² and Sara Marsal¹, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²IMIDomics, Barcelona, Spain, ³Hospital General Universitario de Alicante, Rheumatology, Alicante, Spain, ⁴Hospital Regional Universitario Carlos Haya, Rheumatology, Málaga, Spain, ⁵Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Spain, ⁶Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Madrid, Spain, ⁷Hospital Universitario de Araba, Rheumatology, Vitoria, Spain, ⁸Hospital Universitario de Guadalajara, Rheumatology, Guadalajara, Spain, ⁹Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ¹⁰Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain, ¹¹Hospital Universitario La Princesa, Rheumatology, Madrid, Spain, ¹²Hospital Universitari Germans Trias i Pujol, Dermatology, Badalona, Spain, ¹³Complejo Hospitalario Universitario de A Coruña, Dermatology, A Coruña, Spain, ¹⁴Hospital Universitario de Donostia, Gastroenterology, San Sebastián, Spain, ¹⁵Hospital Universitario Reina Sofía, Gastroenterology, Córdoba, Spain, ¹⁶Charité-Universitätsmedizin Berlin, Gastroenterology, Berlin, Germany, ¹⁷University of Verona, Dermatology, Verona, Spain, ¹⁸Centre for Genomic Regulation (CNAG-CRG), Barcelona, Spain, ¹⁹Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelonoa, Spain, ²⁰Hospital Clínic-IDIBAPS, Barcelona, Spain, ²¹HudsonAlpha Institute for Biotechnology, Huntsville, AL, ²²Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, United Kingdom
Background/Purpose: Targeted therapies have revolutionized the management of immune-mediated inflammatory diseases (IMIDs), however, there is a substantial number of patients who respond poorly to a…
Abstract Number: 0003 • ACR Convergence 2025
In Vivo Generation of anti-CD19 CAR T Cells Utilizing Circular RNA Encapsulated in Targeted Lipid Nanoparticles
Xiaoyu Pan¹, Xiaoning Wang¹, Zhihao Chen¹, Xiaowen Zou¹, Siqi Li¹, Jian Ye¹, Fei Lin¹, Yang He¹, Edo Kon², Peng Zhu¹, Mengyun Chen¹ and Weiyi Zhang¹, ¹RiboX Therapeutics, Shanghai, China (People's Republic), ²RiboX Therapeutics, Cambridge, MA
Background/Purpose: Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized cancer treatment and shown promise in addressing autoimmune diseases. However, current ex vivo CAR T-cell therapies…
Abstract Number: 0036 • ACR Convergence 2025
Integrated Analysis of Polygenic and Environmental Risk Scores for Late-Onset Systemic Lupus Erythematosus
Mehmet Hocaoglu¹ and Amr Sawalha², ¹University of Pittsburgh Medical Center, Piitsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Polygenic risk scores (PRS) have been constructed to summarize genetic risk but there is limited research on environment-wide analysis of risk factors for systemic…
Abstract Number: 0048 • ACR Convergence 2025
Integrative Spatial Proteomics and Single-Cell RNA Sequencing Unveil Molecular Complexity in Rheumatoid Arthritis for Novel Therapeutic Targeting
Xue Wang¹, Fei Wang², Sílvia Sisó², Archana Iyer², Heather Knight², Lori Duggan², Yingli Yang², Liang Jin², Baoling Cui², Yupeng He³, Jan Schejbal², Lucy Phillips², Bohdan Harvey⁴ and Yu Tian², ¹AbbVie, South San Francisco, CA, ²AbbVie, Worcester, MA, ³AbbVie, North Chicago, IL, ⁴AbbVie, Cambridge, MA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by persistent inflammation, fibroblast proliferation and progressive joint damage. Understanding the heterogeneity of RA and…
Abstract Number: 0034 • ACR Convergence 2025
Meta-Analysis of GWAS data from 10,003 Sjögren’s Disease Cases Identifies Thirteen Sjögren’s Risk Loci.
Marcin Radziszewski¹, Bhuwan Khatri¹, Philip Stuart², Astrid Rasmussen¹, Kandice Tessneer¹, Cherilyn Pritchett-Frazee¹, Matthew Pattrick², Elena Pontarini³, michele Bombardieri⁴, Maureen Rischmueller⁵, Marika Kvarnström⁶, Torsten Witte⁷, Hendrika Bootsma⁸, Gwenny Verstappen⁹, Frans Kroese⁹, Arjan Vissink¹⁰, Sarah Pringle⁹, Athanasios Tzioufas¹¹, Clio Mavragani¹², Alan Baer¹³, Marta Alarcon-Riquelme¹⁴, Javier Martin¹⁵, Xavier Mariette¹⁶, Gaetane Nocturne¹⁷, Jacques-Olivier Pers¹⁸, Jacques-eric GOTTENBERG¹⁹, Wan-Fai Ng²⁰, Caroline Shiboski²¹, Kimberly Taylor²², Lindsey Criswell²³, Blake M. Warner²⁴, A. Darise Farris¹, Judith James¹, R Hal Scofield¹, Joel Guthridge¹, Daniel Wallace²⁵, Swamy Venuturupalli²⁶, Mike Brennan²⁷, Juliana Imgenberg-Kreuz²⁸, Lars Rönnblom²⁸, Eva Baecklund²⁹, Maija-Leena Eloranta²⁸, Svein Joar Augländ Johnsen³⁰, Roald Omdal³¹, Lara Aqrawi³², Øyvind Palm³³, Johan Brun³⁴, Daniel Hammenfors³⁴, Malin Jonsson³⁴ and Silke Appel³⁴, Sara Bucher³⁵, Helena Forsblad³⁶, Thomas Mandl³⁷, Per Eriksson³⁸, Marie Wahren-Herlenius⁶, Erik Abner³⁹, Tõnu Esko³⁹, Benjamin A. Fisher⁴⁰, Rachel Gordon⁴¹, Gabriela Hernandez-Molina⁴², Adrian Lee⁴³, Johann Gudjonsson⁴⁴, Lam Tsoi⁴⁴, Gunnel Nordmark²⁹ and Christopher Lessard¹,¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Michigan Medical School, Ann Arbor, MI, ³Queen Mary University of London, London, United Kingdom, ⁴Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, ⁵RheumatologySA, Adelaide, Australia, ⁶Karolinska Institutet, Stockholm, Sweden, ⁷Dept of Rheumatology and Immunology, Hannover, Niedersachsen, Germany, ⁸UMCG, Groningen, Netherlands, ⁹University Medical Center Groningen, Groningen, Netherlands, ¹⁰University of Groningen, Leek, Netherlands, ¹¹LAIKO HOSPITAL, Athens, Greece, ¹²National and Kapodistrian University of Athens, Athens, Greece, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹⁵Department of Cell Biology and Immunology, Institute of Parasitology and Biomedicine López-Neyra, CSIC, Granada, Spain, ¹⁶Université Paris-Saclay, Le Kremlin Bicetre, France, ¹⁷University Paris Saclay, Le Kremlin Bicetre, Ile-de-France, France, ¹⁸CHU de Brest, Brest, France, ¹⁹Hautepierre Hospital, STRASBOURG, Alsace, France, ²⁰Newcastle University, Gateshead, United Kingdom, ²¹University of California San Francisco, San Francisco, CA, ²²UC San Francisco, San Francisco, CA, ²³NIH/NHGRI, Bethesda, MD, ²⁴National Institutes of Health, Bethesda, MD, ²⁵Cedars Sinai Medical Center, Studio City, CA, ²⁶Attune Health, Beverly Hills, CA, ²⁷Atrium Health, Charlotte, NC, ²⁸Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²⁹Uppsala University, Uppsala, Sweden, ³⁰Stavanger University Hospital, Stavanger, Norway, ³¹Stavanger University Hospital, Stavanger, Nepal, ³²Kristiania University College, Oslo, Norway, ³³Oslo University Hospital, Oslo, Norway, ³⁴University of Bergen, Bergen, Norway, ³⁵Örebro University, Örebro, Sweden, ³⁶University of Gothenburg, Gothenburg, Sweden, ³⁷Lund University, Malmö, Sweden, ³⁸Linköping University, Linköping University, ³⁹University of Tartu, Tartu, Estonia, ⁴⁰ King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, ⁴¹University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴²Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ⁴³University of Sydney, Sydney, Australia, ⁴⁴University of Michigan, Ann Arbor, MI.

Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune condition with a complex genetic architecture. To date, 22 genome-wide significant (GWS) SjD risk loci have been…

« Previous Page
1
…
3
4
5
6
7
…
2607
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].